
Ipamorelin Enhances Cognitive Function in Early-Onset Alzheimer’s: A 5-Year Study
Reading Time: 2 minutes Introduction Alzheimer’s disease remains a formidable challenge in the realm of neurodegenerative disorders, particularly when it manifests at an early age. Early-onset Alzheimer’s disease, which affects individuals under the age of 65, can have profound impacts on cognitive function and quality of life. In the quest for effective interventions, the potential of Ipamorelin, a growth hormone secretagogue, has garnered attention. This article delves into a five-year prospective study examining the influence of Ipamorelin on cognitive function in American males diagnosed with early-onset Alzheimer’s disease. Study Design and Methodology The study involved 150 American males diagnosed with early-onset Alzheimer’s disease, aged...